POLG — DNA Polymerase Subunit Gamma

POLG — DNA Polymerase Subunit Gamma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">polg</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POLG</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DNA Polymerase Subunit Gamma</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q25</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5428</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>174763</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000140521</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9UQF2</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>DNA polymerase, family A</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alpers-Huttenlocher Syndrome, PEO, Parkinson's Disease, Alzheimer's Disease, Mitochondrial DNA Depletion Syndrome</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Polymerase domain</td>
<td>aa 1-600</td>
</tr>
<tr>
<td class="label">Linker region</td>
<td>aa 600-800</td>
</tr>
<tr>
<td class="label">Exonuclease domain</td>
<td>aa 800-1100</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>aa 1100-1239</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TWNK</td>
<td>DNA helicase, unwinds mtDNA</td>
</tr>
<tr>
<t

POLG — DNA Polymerase Subunit Gamma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">polg</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POLG</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DNA Polymerase Subunit Gamma</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q25</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5428</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>174763</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000140521</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9UQF2</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>DNA polymerase, family A</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alpers-Huttenlocher Syndrome, PEO, Parkinson's Disease, Alzheimer's Disease, Mitochondrial DNA Depletion Syndrome</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Polymerase domain</td>
<td>aa 1-600</td>
</tr>
<tr>
<td class="label">Linker region</td>
<td>aa 600-800</td>
</tr>
<tr>
<td class="label">Exonuclease domain</td>
<td>aa 800-1100</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>aa 1100-1239</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TWNK</td>
<td>DNA helicase, unwinds mtDNA</td>
</tr>
<tr>
<td class="label">mtSSB</td>
<td>Single-stranded DNA binding</td>
</tr>
<tr>
<td class="label">POLRMT</td>
<td>RNA polymerase, primers</td>
</tr>
<tr>
<td class="label">TFAM</td>
<td>Transcription factor, mtDNA packaging</td>
</tr>
<tr>
<td class="label">TP</td>
<td>Mitochondrial RNA primer</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Tissues Affected</td>
</tr>
<tr>
<td class="label">MTDPS1</td>
<td>Muscle</td>
</tr>
<tr>
<td class="label">MTDPS4</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">MTDPS7</td>
<td>Liver</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
</table>

Pathway Diagram

Introduction

POLG (DNA Polymerase Subunit Gamma) encodes the catalytic subunit of the mitochondrial DNA polymerase, which is the sole DNA polymerase responsible for replication and maintenance of the mitochondrial genome. This 1239-amino acid protein is essential for the propagation of mitochondrial DNA (mtDNA) and contains both polymerase activity for DNA synthesis and 3'-5' exonuclease activity for proofreading. POLG is one of the most commonly mutated genes in mitochondrial disease, with over 300 pathogenic variants identified that cause a spectrum of disorders ranging from Alpers-Huttenlocher syndrome (a severe childhood encephalopathy) to progressive external ophthalmoplegia (PEO) and late-onset parkinsonism. [@polg_mtdna_2024]

The mitochondrial genome is a compact, circular DNA molecule encoding 13 essential components of the oxidative phosphorylation (OXPHOS) system, along with the rRNA and tRNA genes required for their translation. POLG maintains this genome throughout life, and its proper function is critical for cellular energy production, particularly in tissues with high metabolic demands such as [neurons](/entities/neurons), [cardiac muscle](/cell-types/cardiac-muscle), and skeletal muscle. The central role of POLG in mtDNA maintenance links it to the pathogenesis of multiple neurodegenerative diseases, including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and age-related neurodegeneration. [@polg_neurodegeneration_2021]

Overview

Function

POLG is the catalytic engine of the mitochondrial DNA replication machinery, one of the essential components of the mtDNA replisome that includes the helicase TWNK (Twinkle), the single-stranded DNA-binding protein (mtSSB), and the mitochondrial RNA polymerase (POLRMT). POLG synthesizes both the leading and lagging strands of the circular mtDNA molecule in a processive manner, and its intrinsic proofreading activity ensures high fidelity of mtDNA replication. The enzyme can also participate in base excision repair (BER) of damaged mtDNA, making it important for mtDNA repair and genome stability. [@polg_replication_2022]

Polymerase Activity

The primary function of POLG is the synthesis of mtDNA:

The polymerase domain resides in the N-terminal half of the protein and contains the active site for nucleotidyl transfer. The enzyme can incorporate dNTPs with high efficiency and accuracy, using the mitochondrial dNTP pool which is distinct from the nuclear pool. [@polg_structure_2017]

Proofreading Activity

POLG contains a 3'-5' exonuclease domain that provides proofreading capability:

• Mismatch removal: Excises incorrectly incorporated nucleotides
• Fidelity enhancement: Improves replication accuracy 10-100 fold
• Disease relevance: Mutations affecting exonuclease activity cause accumulation of point mutations

Base Excision Repair

POLG participates in mitochondrial BER:

• 5'-dRP lyase activity: Removes damaged 5'-deoxyribose phosphate groups
• Gap filling: Completes repair synthesis after base removal
• DNA damage tolerance: Helps cells survive mtDNA damage

mtDNA Maintenance

Beyond replication, POLG is essential for mtDNA maintenance:

• Genome integrity: Prevents mtDNA deletions and rearrangements
• Nucleoid organization: Interacts with TFAM in mtDNA packaging
• Copy number control: Regulates mtDNA copy number
• Inheritance: Ensures proper transmission of mtDNA to daughter cells

Molecular Mechanisms

Structure-Function Relationship

POLG contains several functional domains:

The full-length POLG protein functions as a homodimer, with each monomer capable of independent catalytic activity. Dimerization enhances processivity and stability during replication. [@polg_structure_2017]

The Mitochondrial Replisome

POLG works in concert with other mtDNA replication proteins:

The coordinated activity of these proteins ensures efficient and accurate mtDNA replication. Mutations in any component can cause mtDNA maintenance disorders. [@polg_twinkle_2019]

mtDNA Mutation Accumulation

A key aspect of POLG-related disease is the accumulation of mtDNA mutations:

This process underlies both inherited mitochondrial disease and age-related neurodegeneration. [@polg_clonality_2012]

Disease Associations

Alpers-Huttenlocher Syndrome

Alpers-Huttenlocher syndrome (AHS) is the most severe POLG-related disorder:

Clinical Features

• Childhood onset: Typically presents between 2-4 years of age
• Progressive encephalopathy: Developmental regression, seizures, cortical blindness
• Liver failure: Hepatomegaly, elevated transaminases, hepatic failure
• Drug-induced liver toxicity: Valproic acid can trigger catastrophic liver failure
• mtDNA depletion: Severe reduction in mtDNA copy number

Molecular Basis

• Biallelic POLG mutations: Usually compound heterozygous
• Severe enzyme deficiency: Mutations that abolish enzyme function
• Tissue-specific vulnerability: Liver and brain particularly affected
• Environmental triggers: Valproic acid, viral infections

Progressive External Ophthalmoplegia (PEO)

PEO is characterized by:

PEO can be inherited in autosomal dominant or autosomal recessive patterns, with dominant forms typically caused by POLG mutations. The disease is often asymmetric and progresses slowly over decades. [@polg_peo_2022]

Parkinson's Disease

POLG is increasingly recognized in [Parkinson's disease/diseases/parkinsons-disease) pathogenesis:

Evidence for POLG Involvement

• Genetic association: POLG variants increase PD risk
• mtDNA defects: Multiple mtDNA deletions in PD substantia nigra
• Dopaminergic neuron vulnerability: High energy demand makes neurons susceptible
• PINK1/PARKIN connection: Mitochondrial quality control pathways intersect

Clinical Features

• Early-onset PD: POLG-associated parkinsonism often presents before age 50
• Additional features: May include PEO, myopathy
• Response to treatment: May respond to standard PD therapies initially

Alzheimer's Disease

In [Alzheimer's disease/diseases/alzheimers-disease), POLG dysfunction contributes to pathogenesis:

The relationship between POLG and AD is bidirectional—AD increases mtDNA damage while impaired POLG accelerates AD pathology. [@polg_ad_2015]

Mitochondrial DNA Depletion Syndrome (MTDPS)

POLG mutations are a major cause of MTDPS:

MTDPS results from inadequate mtDNA copy number, leading to insufficient mitochondrial genomes for normal function. Severity depends on residual POLG activity. [@polg_mds_2023]

Therapeutic Approaches

Nucleoside Supplementation Therapy

For mtDNA depletion syndromes:

• Deoxynucleoside administration: Oral supplementation with dAMP, dGMP
• Rationale: Bypasses defective POLG activity by providing substrate
• Efficacy: Some patients show improved mtDNA copy number and clinical outcomes
• Status: Available for some MTDPS forms

Gene Therapy

Viral vector-based approaches:

• AAV vectors: Can deliver POLG or TWNK to mitochondria
• Mitochondrial targeting: Sequences to direct proteins to mitochondria
• Challenge: Delivering genes to mitochondria remains technically difficult
• Progress: Preclinical studies show promise

Antioxidant Therapy

Supporting mitochondrial function:

• CoQ10: Electron carrier and antioxidant
• MitoQ: Mitochondria-targeted antioxidant
• Vitamin C/E: General antioxidants
• Efficacy: May slow progression in some patients

Disease Management

Supportive care for POLG disorders:

• Seizure control: Antiepileptic medications (avoid valproic acid in AHS)
• Liver support: Monitoring and supportive care for hepatic involvement
• Physical therapy: For myopathy and PEO
• Genetic counseling: Family planning and carrier testing

Expression Pattern

Tissue Distribution

POLG is expressed in all tissues with highest levels in:

Cellular Localization

• Mitochondria: Primary location, matrix and inner membrane
• Mitochondrial nucleoids: Associated with TFAM on mtDNA

Animal Models

Knockout Models

• Polg knockout mice: Embryonic lethal, complete mtDNA loss
• Conditional knockouts: Tissue-specific deletion reveals organ-specific requirements
• Heterozygous mice: Viable with subtle mitochondrial dysfunction

Mutator Mice

• Polg mutator mice: Express proofreading-deficient POLG
• Accelerated aging: Develop mtDNA mutations, aging phenotypes
• Neurodegeneration: Show age-related neuronal loss

Aging and POLG

POLG is central to aging biology:

The Polg mutator mouse demonstrates that accelerating mtDNA mutations is sufficient to cause premature aging phenotypes, establishing mtDNA maintenance as a key determinant of organismal aging. [@polg_aging_2021]

Key Publications

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alpers-Huttenlocher Syndrome](/diseases/alpers-huttenlocher)
• [Progressive External Ophthalmoplegia](/diseases/progressive-external-ophthalmoplegia)
• [Mitochondrial DNA Depletion Syndrome](/diseases/mtdna-depletion)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [TFAM](/genes/tfam)
• [TWNK](/genes/twnk)

External Links

• [NCBI Gene: POLG](https://www.ncbi.nlm.nih.gov/gene/5428)
• [UniProt: Q9UQF2](https://www.uniprot.org/uniprot/Q9UQF2)
• [OMIM: 174763](https://www.omim.org/entry/174763)
• [Ensembl: ENSG00000140521](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140521)
• [MITOMAP: POLG](https://www.mitomap.org/foswiki/bin/view/MITOMAP/PolG)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving POLG — DNA Polymerase Subunit Gamma discovered through SciDEX knowledge graph analysis: